Trial Profile
Observational Prospective Study of Survival, Treatment Patterns, Disease and Economic Outcomes in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Progression During or After a First-line Docetaxel-based Regimen.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 29 Aug 2016
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Antineoplastics; Taxanes
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms PORTREAT
- Sponsors Sanofi
- 29 Aug 2012 New source identified and integrated (German Clinical Trials Register: DRKS00004060).
- 11 Feb 2011 Actual end date (1 Oct 2010) added as reported by ClinicalTrials.gov.
- 11 Feb 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.